- Conditions
- Non Small Cell Lung Cancer, Small-cell Lung Cancer
- Interventions
- Fingolimod 0.5 milligram (mg) [Gilenya]
- Drug
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Capmatinib, Spartalizumab, Docetaxel
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Fayetteville, Arkansas
- Conditions
- Small Cell Lung Cancer
- Interventions
- topotecan/cisplatin, etoposide/cisplatin
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 760 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2001
- U.S. locations
- 66
- States / cities
- Hoover, Alabama • Chula Vista, California • Fountain Valley, California + 57 more
- Conditions
- Pulmonary Diseases, Neoplasms, Lung
- Interventions
- Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Taxol (paclitaxel), Radiotherapy, Carboplatin, Gemcitabine
- Drug · Procedure
- Lead sponsor
- Leo W. Jenkins Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2017
- U.S. locations
- 1
- States / cities
- Greenville, North Carolina
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Vorinostat, Bevacizumab, Carboplatin, Paclitaxel
- Drug
- Lead sponsor
- Milton S. Hershey Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2016
- U.S. locations
- 1
- States / cities
- Hershey, Pennsylvania
- Conditions
- Lung Cancer
- Interventions
- cisplatin, docetaxel, etoposide, conventional surgery, radiation therapy
- Drug · Procedure · Radiation
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- Not listed
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2010
- U.S. locations
- 154
- States / cities
- Mobile, Alabama • Fort Collins, Colorado • Jacksonville, Florida + 97 more
- Conditions
- Colorectal Cancer, Melanoma, Non-small Cell Lung Cancer
- Interventions
- Not listed
- Lead sponsor
- Natera, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 290 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- San Carlos, California
- Conditions
- Non-small Cell Lung Cancer (NSCLC), Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Carcinoma, Non Small Cell Lung Cancer, Non Small Cell Lung Carcinoma
- Interventions
- azacytidine, carboplatin, paclitaxel, durvalumab, cisplatin, gemcitabine, pemetrexed
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2034
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Small Cell Lung Cancer
- Interventions
- Gocatamig, Ifinatamab Deruxtecan (I-DXd), Durvalumab
- Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 262 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 9
- States / cities
- Aurora, Colorado • Miami, Florida • Chicago, Illinois + 6 more
- Conditions
- Small Cell Lung Carcinoma
- Interventions
- Amuvatinib
- Drug
- Lead sponsor
- Astex Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 7
- States / cities
- Aurora, Colorado • Atlanta, Georgia • Louisville, Kentucky + 4 more
- Conditions
- Non-Small Cell Lung Cancer (NSCLC) With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy
- Interventions
- OSI-906, erlotinib, placebo
- Drug
- Lead sponsor
- Astellas Pharma Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 205 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 7
- States / cities
- Jacksonville, Florida • Port Saint Lucie, Florida • Albany, Georgia + 4 more
- Conditions
- Small Cell Lung Cancer
- Interventions
- Carboplatin, Placebo, Trilaciclib, Etoposide
- Drug
- Lead sponsor
- G1 Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 122 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 26
- States / cities
- Hot Springs, Arkansas • Rogers, Arkansas • Whittier, California + 22 more
- Conditions
- SCLC
- Interventions
- ZL-1310, Atezolizumab, Carboplatin
- Drug
- Lead sponsor
- Zai Lab (Shanghai) Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 339 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 11
- States / cities
- Duarte, California • New Haven, Connecticut • Sarasota, Florida + 8 more
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Rociletinib, MPDL3280A
- Drug
- Lead sponsor
- Clovis Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Santa Monica, California
- Conditions
- Non-small Cell Lung Cancer, Squamous Lung Dysplasia
- Interventions
- placebo, inositol
- Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 45 Years to 79 Years
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2014
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Rochester, Minnesota • Albuquerque, New Mexico
- Conditions
- Advanced Cancer, Metastatic Cancer, Malignant Neoplasm of Colon, Malignant Neoplasm of Lung, Malignant Neoplastic Disease
- Interventions
- MRTX849, BI 1701963
- Drug
- Lead sponsor
- Mirati Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 4
- States / cities
- St Louis, Missouri • Cleveland, Ohio • Houston, Texas + 1 more
- Conditions
- KRAS G12D Mutation, Advanced Solid Cancer
- Interventions
- ARV-806
- Drug
- Lead sponsor
- Arvinas Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 159 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • New Haven, Connecticut • Tampa, Florida + 9 more
- Conditions
- Patients With Non-Small Cell Lung Cancer
- Interventions
- OSE2101, Docetaxel, NGS HLAA2 assay
- Drug · Device
- Lead sponsor
- OSE Immunotherapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 363 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 79
- States / cities
- Beverly Hills, California • Encino, California • Los Angeles, California + 56 more
- Conditions
- Breast Cancer, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer, Lung Cancer, Ovarian Cancer, Prostate Cancer
- Interventions
- Taxotere (Docetaxel), Alimta (Pemetrexed)
- Drug
- Lead sponsor
- University of Arizona
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2014
- U.S. locations
- 1
- States / cities
- Tucson, Arizona
- Conditions
- Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
- Interventions
- Questionnaire Administration, Stereotactic Radiosurgery
- Other · Radiation
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Bevacizumab (Avastin), Carboplatin, Docetaxel
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2017
- U.S. locations
- 2
- States / cities
- Houston, Texas
- Conditions
- Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7
- Interventions
- Laboratory Biomarker Analysis, Osimertinib, Pharmacological Study, Sapanisertib
- Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 3
- States / cities
- New Haven, Connecticut • Tampa, Florida
- Conditions
- Anxiety Disorder, Head and Neck Cancer, Lung Cancer
- Interventions
- Medical chart review, Liebowitz Social Anxiety Scale and the Social Phobia and Anxiety Inventory, management of therapy complications, Structured Clinical Interview for the Diagnostic and Statistical Manual-IV SCID, Functional Assessment of Cancer Therapy-General (FACT-G)
- Other · Procedure
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 21 Years to 70 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2008
- U.S. locations
- 2
- States / cities
- Nashville, Tennessee